Evidence map›Paper›PMID 42855519›Full record

ArticleEMBO molecular medicine2026

Activated protein C promotes hematopoietic stem and progenitor cell quiescence and engraftment.

Simon J Pöllmann, Marcel G E Rommel, Leal Oburoglu, Tanja Hirch, Fabiola Valdivia-Francia, Kah Mun Siow, Timon Menzi, Julia Ackva, Franziska Schenk, Matthias J Neeracher and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Simon J PöllmannDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.
Marcel G E RommelInstitute for the Biology of Stem Cells, University of California, Santa Cruz, CA, 95064, USA.
Leal OburogluDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.
Tanja HirchDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.ORCID http://orcid.org/0000-0002-7989-972X
Fabiola Valdivia-FranciaTranslational Stem Cell Biology, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.
Kah Mun SiowDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.
Timon MenziDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.ORCID http://orcid.org/0009-0005-9634-0054
Julia AckvaDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.ORCID http://orcid.org/0009-0000-2223-923X
Franziska SchenkDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.
Matthias J NeeracherDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.ORCID http://orcid.org/0009-0007-4274-5595
Ataman SendoelTranslational Stem Cell Biology, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.
Janine ReichenbachDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland.ORCID http://orcid.org/0000-0002-9008-1312
E Camilla ForsbergInstitute for the Biology of Stem Cells, University of California, Santa Cruz, CA, 95064, USA.ORCID http://orcid.org/0000-0002-8740-4299
Ute ModlichDivision of Gene and Cell Therapy, Institute for Regenerative Medicine (IREM), University of Zurich, 8952, Schlieren, Switzerland. ute.modlich@irem.uzh.ch.ORCID http://orcid.org/0000-0001-8018-4118

Funding

Replacement and enhancement of Cell Sorting capabilities at UCSCS10OD036313 · OD · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI CARPENTER, SUSAN · 2025 to 2025
$749k
California Institute for Regenerative Medicine (CIRM) DISC0-14366California Institute for Regenerative Medicine (CIRM) EDUC4-12759Deutsche Forschungsgemeinschaft (DFG) MO 860/3-3Gordon and Betty Moore Foundation (GBMF) GBMF13917HHS | NIH | NIH Office of the Director (OD) 1S10OD030423-01HHS | NIH | NIH Office of the Director (OD) S10OD036313
6 · The paper itself

Abstract

Hematopoietic stem cells (HSCs) are the definitive source of all blood cells and replenish them for life. The endothelial protein C receptor (EPCR) which signals via its coreceptor protease-activated receptor 1 (PAR1) is expressed on a subpopulation of highly quiescent HSCs with high engraftment potential after transplantation. We demonstrate that EPCR/PAR1 on human CD34

Identifiers

PMID42855519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.